Helse Møre og Romsdal HF   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Alesund Norway (2011)

Organization Overview

First Clinical Trial
2011
NCT00248703
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Alesund Hospital | Ålesund Hospital, Norway | Helse Møre og Romsdal HF | Helse Møre & Romsdal HF, Ålesund Hospital | More and Romsdal Health Trust | Møre and Romsdal Health Trust | More and Romsdal Hospital Trust | Møre og Romsdal Hospital Trust | Møre og Romsdal Hospital Trust (Helse Møre og Romsdal), Kristiansund Hospital | Møre & Romsdal Hospital Trust, Ålesund Hospital

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 4)

Chlamydia Infections (Phase 2)

Chronic Pain (Phase 3)

Communicable Diseases (Phase 2)

Dementia (Phase 4)

Hemorrhage (Phase 4)

Infections (Phase 2)

Irritable Bowel Syndrome (Phase 3)

Lung Neoplasms (Phase 2)

Multiple Myeloma (Phase 3)

Pneumonia (Phase 4)

Postoperative Hemorrhage (Phase 4)

Respiratory Tract Infections (Phase 4)

Rotator Cuff Injuries (Phase 3)

Seroma (Phase 4)

Small Cell Lung Carcinoma (Phase 2)

Syndrome (Phase 3)

Tendinopathy (Phase 3)

Urethritis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 22
  • # of Trial APIs: 26